Cyclosporine Oral Solution Suppliers & Bulk Manufacturers

Available Forms: Oral Solution

Available Strengths: 100 mg/ml

Reference Brands: Gengraf (USA), Neoral (USA)

Category: Immune Disorder

Cyclosporine is used to prevent organ rejection in people who have received a liver, kidney, or heart transplant. It is usually taken along with other medications to allow your new organ to function normally. Cyclosporine belongs to a class of drugs known as immunosuppressants. Cyclosporine Oral Solution is available in Oral Solution and strengths such as 100 mg/ml. Sourced from GMP-certified and ISO-compliant manufacturers, this API meets global pharmacopeia standards (USP/EP/JP as applicable). Ideal for pharmaceutical formulation and commercial manufacturing, Cyclosporine Oral Solution is supplied in bulk quantities with complete regulatory support including DMF, COA, and MSDS.

Cyclosporine Oral Solution can be exported to over 30 countries across Asia, Africa, Europe, and Latin America. Flexible packaging, competitive pricing, and a verified supplier network make Pharmatradz a trusted sourcing partner for pharmaceutical companies and contract manufacturers worldwide.

Product Description:

Cyclosporine is a potent immunosuppressive agent widely used to prevent organ rejection following allogeneic transplantation, particularly in kidney, liver, and heart transplant patients. It works by selectively inhibiting T-lymphocyte activation, thereby suppressing immune responses that can lead to graft rejection. Due to its targeted immunomodulatory action, cyclosporine plays a critical role in transplant medicine.

Beyond transplantation, cyclosporine is also indicated for the management of several autoimmune and inflammatory disorders. These include severe rheumatoid arthritis in patients who have shown an inadequate response to methotrexate, psoriasis, nephrotic syndrome, uveitis, and certain dermatological and ophthalmic conditions. In addition, it is used as a second-line treatment option in conditions such as graft-versus-host disease and amyotrophic lateral sclerosis (ALS), along with other FDA-approved and non-FDA-approved indications where immune suppression is clinically beneficial.

Cyclosporine exerts its effect by inhibiting calcineurin, which blocks the transcription of interleukin-2 and other cytokines essential for T-cell activation. Due to its narrow therapeutic index, treatment requires careful dosing, therapeutic drug monitoring, and regular assessment of renal function and other safety parameters. Cyclosporine remains a cornerstone therapy in immunosuppressive treatment protocols worldwide.